Clinical trial
A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
NCT01145989 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- NCIC Clinical Trials Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 15, 2011
- Completion date
- November 27, 2015
- Enrollment
- 8 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.